Here are the DEF 14A proxy statements from Atea Pharmaceuticals, Inc. (AVIR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AVIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVIR filings page.
Atea Pharmaceuticals is asking stockholders to approve three main items at its 2026 virtual annual meeting: electing three Class III directors until 2029, ratifying KPMG as auditor for 2026, and an advisory vote on executive pay. Holders of common stock at the April 24, 2026 record date may vote.
The proxy also highlights business progress. Atea is advancing a Phase 3 regimen of bemnifosbuvir and ruzasvir for chronic hepatitis C, with topline data from the C‑BEYOND trial expected mid‑2026 and C‑FORWARD by year‑end 2026. Earlier Phase 2 data showed a 98% sustained virologic response 12 weeks after treatment among adherent patients.
Management reports a roughly 25% workforce reduction in early 2025, projected to save about $15 million through 2027, and completion of a $25 million stock repurchase program that retired 7,673,792 shares. The board emphasizes a classified structure, majority‑independent membership, and a pay‑for‑performance executive compensation program with most CEO target pay at risk and more than half of 2025 equity value in performance stock units.